Cell freezing medium is a complete cell freezing media for mammalian cell cultures.
Most classic formulations of cell freezing media containing dimethyl sulfoxide (DMSO) as the active freezing agent. However, since it is known that DMSO is a mutagen and carcinogen, DMSO-free formulations are becoming popular for stem cell applications. This is an especially critical consideration for cells being used in translational research or clinical applications. Moreover, media formulations that are manufactured under GMP compliance and have drug-master files registered with government regulatory agencies provide added value for regenerative medicine use.
Due to the COVID-19 pandemic, the global Cell Freezing Media for Cell Therapy market size is estimated to be worth US$ 79 million in 2021 and is forecast to a readjusted size of US$ 198.8 million by 2028 with a CAGR of 13.8% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Cell Freezing Media for Cell Therapy market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Cell Freezing Media for Cell Therapy landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Market competition is intense. BioLife Solutions, Thermo Fisher Scientific, Merck, Cytiva, Zenoaq, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. The Top 5 manufacturers occupied 84.84% of global market share in 2021.
This report focuses on Cell Freezing Media for Cell Therapy volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Cell Freezing Media for Cell Therapy market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe and Japan, etc.
Global Cell Freezing Media for Cell Therapy Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
With FBS
Without FBS
Segment by Application
Human Embryonic Stem Cells
CAR-T Cell Therapy
Neural Stem Cell Therapy
Mesenchymal Stem Cell Therapy
Hematopoietic Stem Cell Transplantation
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
BioLife Solutions
Thermo Fisher Scientific
Merck
Cytiva
Zenoaq
WAK-Chemie Medical
Sartorius
Akron Biotechnology
Sansheng Bio
Youkang Bio